This article is more than 5 years old. Information may no longer be current.

VIDEO: Immunotherapy combination demonstrates efficacy in advanced ovarian cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Frederic Ors, BSc, CEO of IMV — a clinical stage immuno-oncology corporation — spoke with HemOnc Today about key data the company presented at ASCO Annual Meeting.

An oral presentation included positive data from the DeCidE1 study, which evaluated DPX-Survivac (IMV) — a T cell-activating immunotherapy that targets survivin — in combination with low-dose cyclophosphamide and epacadostat (INCB024360, Incyte), an IDO1 inhibitor.

The phase 1b/phase 2 trial included women with advanced recurrent ovarian cancer.

Other trials are underway to assess DPX-Survivac in combination with the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) for treatment of ovarian cancer and diffuse large B-cell lymphoma.